» Authors » Barry N Kreiswirth

Barry N Kreiswirth

Explore the profile of Barry N Kreiswirth including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 330
Citations 15243
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang J, Long T, Porter A, Lovey A, Lee A, Jacob J, et al.
Emerg Infect Dis . 2025 Mar; 31(4). PMID: 40072602
Carbapenem-resistant and virulence plasmid-harboring Klebsiella pneumoniae (pVir-CRKP) has emerged and spread globally, yet clinical investigations from the United States remain limited. We conducted a genomic analysis of 884 unique carbapenem-resistant...
2.
Wei J, Huang J, Zou C, Shen S, Kreiswirth B, Huang A, et al.
mSystems . 2025 Mar; :e0018425. PMID: 40067047
carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive. To better elucidate these...
3.
Jiang J, Cienfuegos-Gallet A, Long T, Peirano G, Chu T, Pitout J, et al.
Genome Med . 2025 Feb; 17(1):13. PMID: 39994790
No abstract available.
4.
Jiang J, Cienfuegos-Galletd A, Cienfuegos-Gallet A, Long T, Peirano G, Chu T, et al.
Genome Med . 2025 Jan; 17(1):9. PMID: 39885543
Background: Klebsiella pneumoniae is one of the most prevalent pathogens responsible for multiple infections in healthcare settings and the community. K. pneumoniae CG147, primarily including ST147 (the founder ST), ST273,...
5.
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, et al.
Antimicrob Agents Chemother . 2024 Dec; 69(2):e0117424. PMID: 39714147
() presents significant clinical challenges. This study evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against and explored the underlying mechanisms. Synergy was assessed through MIC tests...
6.
Jiang J, Komarow L, Hill C, Boutzoukas A, Hanson B, Arias C, et al.
J Infect Dis . 2024 Dec; PMID: 39667036
Background: Despite the global public health threat posed by carbapenem-resistant Enterobacter spp., clinical and molecular epidemiological studies on international isolates remain scarce. Historically, the taxonomy of Enterobacter has been challenging,...
7.
Cristinziano M, Shashkina E, Chen L, Xiao J, Miller M, Doligalski C, et al.
Nat Commun . 2024 Nov; 15(1):10360. PMID: 39609405
Nontuberculous mycobacterium (NTM) infections are challenging to manage and are frequently non-responsive to aggressive but poorly-tolerated antibiotic therapies. Immunosuppressed lung transplant patients are susceptible to NTM infections and poor patient...
8.
Yen K, Terlecky A, Hao M, Cienfuegos V, Rojtman A, Chen L, et al.
J Microbiol Methods . 2024 Sep; 226:107047. PMID: 39303991
We report the creation of 17 Escherichia coli strains harboring the conjugative plasmid pLCasCureT with a CRISPR-Cas9 system to surgically "cure" the most common plasmids among Enterobacterales species. This approach...
9.
Yasmin M, Marshall S, Chen L, Rhoads D, Jacobs M, Rojas L, et al.
Antimicrob Agents Chemother . 2024 Aug; 68(10):e0020824. PMID: 39162528
We characterized the molecular determinants of meropenem-vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC- (KPC-). Whole-genome sequencing was performed to identify mutations associated with MV non-susceptibility. Isolates with elevated MV MICs were...
10.
Malachowa N, Sturdevant D, Porter A, Martin G, Martens C, Nair V, et al.
Microbiol Spectr . 2024 Jun; 12(8):e0048624. PMID: 38916317
Importance: Our understanding of the mechanisms that underlie the development of vancomycin-intermediate (VISA) is incomplete. To provide a more comprehensive view of this process, we compared genome sequences of clonal...